Kanyos Bio, founded in 2015, focuses on developing antigen-specific immune tolerance technology for type-1 diabetes and celiac disease. The company, headquartered in the United States, originated from EPFL in Switzerland in collaboration with its sister company, Anokion. Kanyos aims to leverage Anokion's immunotechnology expertise and Astellas Pharma's clinical translation experience to develop disease-modifying therapies. The latest funding of $16.40M was obtained through a Venture Round investment on 12 June 2015, with participation from Novartis Venture Fund and Novo Ventures. This unique approach and strong backing from prominent investors position Kanyos Bio as an innovative player in the biotechnology and healthcare industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $16.40M | 2 |
|
12 Jun 2015 |
| Venture Round | $10.40M | - | 29 May 2015 |
No recent news or press coverage available for Kanyos Bio.
We care about your data, and we'd love to use cookies make your experience better.
